Product: GeneStrat,VeriStrat
-
Real World Data: Importance of Monitoring Blood Based KRAS Mutations and Immune Status in Patients with advanced NSCLC
-
Real-World Data: Importance of Monitoring KRAS Mutations in Blood
-
Combined plasma cfDNA mutations and a serum proteomic signature may identify non-responders to anti PD-1 treatment in NSCLC
-
Utility of blood-based genomic and proteomic tests for non-small cell lung cancer
-
Blood-based Genomic and Proteomic Testing for Newly Diagnosed Lung Cancer Patients to Facilitate Rapid Treatment Decisions and Prognostic Conversations
-
Shortening time from diagnosis to treatment in NSCLC: are blood-based biopsies the answer?